Waalkes M P, Rehm S, Riggs C W, Bare R M, Devor D E, Poirier L A, Wenk M L, Henneman J R
Inorganic Carcinogenesis Section, National Cancer Institute, Frederick, Maryland.
Cancer Res. 1989 Aug 1;49(15):4282-8.
The ability of zinc acetate to modify the carcinogenic effects of CdCl2 in male Wistar [Crl:(WI)BR] rats was studied over a 2-year period. Groups of rats received a single s.c. injection of Cd (30.0 mumol/kg) in the dorsal thoracic midline or i.m. in the right thigh at time 0. Zinc was given in three separate s.c. doses of 0.1, 0.3, or 1.0 mmol/kg (at -6, 0, and +18 h relative to cadmium) in the lumbosacral area or p.o. at 100 ppm in the drinking water (-2 to +100 weeks). Cadmium treatments (s.c.) resulted in the appearance of tumors at the injection site and in the testes. The incidence of s.c. injection site tumors (mostly mixed sarcomas) was markedly reduced by high dose (1.0 mmol/kg) s.c. zinc (50% reduction) and was almost abolished by p.o. zinc (92% reduction). Testicular tumors (mostly Leydig cell adenomas) induced by s.c. cadmium were reduced in a dose-related fashion by zinc and were found to be highly dependent on the ability of zinc to prevent the chronic degenerative effects of cadmium in the testes. Oral zinc had no effect on s.c. cadmium-induced testicular tumors, while i.m. cadmium alone did not induce these tumors. In rats in which s.c. cadmium-induced testicular tumors and chronic degenerative effects were prevented by zinc (1.0 mmol/kg, s.c.), a marked elevation in prostatic tumors (exclusively adenomas) occurred (control, 9.6%; cadmium plus high zinc 29.6%). Cadmium given i.m., which did not result in testicular tumors or degeneration, also induced an elevated incidence (42.3%) of prostatic tumors, again indicating a dependence on testicular function. Prostatic tumor incidence was also significantly elevated (25.0%) in rats receiving 1.0 mmol/kg zinc, s.c., in combination with i.m. cadmium. These results indicate that zinc inhibition of cadmium carcinogenesis is a complex phenomenon, depending not only on dose and route but also on the target site in question.
在为期2年的时间里,研究了醋酸锌对雄性Wistar [Crl:(WI)BR]大鼠中CdCl₂致癌作用的影响。在时间点0时,给大鼠组在胸背中线皮下注射一次Cd(30.0 μmol/kg)或在右大腿肌肉注射。锌以三种不同的皮下剂量(0.1、0.3或1.0 mmol/kg,相对于镉在-6、0和+18小时)在腰骶部区域给药,或以100 ppm的浓度加入饮用水中口服给药(-2至+100周)。镉处理(皮下注射)导致注射部位和睾丸出现肿瘤。高剂量(1.0 mmol/kg)皮下注射锌显著降低了皮下注射部位肿瘤(大多为混合肉瘤)的发生率(降低了50%),口服锌几乎消除了该部位肿瘤(降低了92%)。皮下注射镉诱导的睾丸肿瘤(大多为Leydig细胞腺瘤),锌以剂量相关的方式使其减少,并且发现其高度依赖于锌预防镉对睾丸的慢性退行性影响的能力。口服锌对皮下注射镉诱导的睾丸肿瘤没有影响,而单独肌肉注射镉不会诱导这些肿瘤。在皮下注射镉诱导的睾丸肿瘤和慢性退行性影响被锌(1.0 mmol/kg,皮下注射)预防的大鼠中,前列腺肿瘤(均为腺瘤)显著增加(对照组为9.6%;镉加高剂量锌组为29.6%)。肌肉注射镉不会导致睾丸肿瘤或退化,但也会使前列腺肿瘤的发生率升高(42.3%),再次表明其对睾丸功能的依赖性。在接受1.0 mmol/kg锌皮下注射并联合肌肉注射镉的大鼠中,前列腺肿瘤发生率也显著升高(25.0%)。这些结果表明,锌对镉致癌作用的抑制是一个复杂的现象,不仅取决于剂量和给药途径,还取决于所涉及的靶位点。